Delcath Systems, Inc. (DCTH) News
Filter DCTH News Items
DCTH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DCTH News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest DCTH News From Around the Web
Below are the latest news stories about DELCATH SYSTEMS INC that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)QUEENSBURY, N.Y., January 03, 2025--Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company’s Compensation Committee, as a material inducement to the employment of an individual whose employment commenced on November 4, 2024. |
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant ExercisesQUEENSBURY, N.Y., December 30, 2024--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exercise provisions. The warrants, issued in July and August 2019 as a component of a private placement, |
3 US Growth Companies To Watch With Up To 32% Insider OwnershipAs the United States stock market navigates a volatile period marked by fluctuations in major indices and a notable slump in big-tech stocks, investors are increasingly focused on identifying resilient growth opportunities. In this environment, companies with substantial insider ownership can offer unique insights into potential value creation, as insiders' vested interests often align with long-term shareholder success. |
Analysts Expect Breakeven For Delcath Systems, Inc. (NASDAQ:DCTH) Before LongWe feel now is a pretty good time to analyse Delcath Systems, Inc.'s ( NASDAQ:DCTH ) business as it appears the company... |
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal CancerQUEENSBURY, N.Y., December 02, 2024--Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the U.S. Food and Drug Administration (FDA) has completed its 30-day review of the Company's Investigational New Drug (IND) application for a Phase 2 clinical trial evaluating HEPZATO™ in combination with standard of care (SOC) for liver-dominant metastatic colorectal cancer (mCRC). With the FDA's revi |
Delcath Systems (NASDAQ:DCTH) jumps 13% this week, taking one-year gains to 330%For many, the main point of investing in the stock market is to achieve spectacular returns. When an investor finds a... |
Delcath Systems Third Quarter 2024 Earnings: Beats ExpectationsDelcath Systems ( NASDAQ:DCTH ) Third Quarter 2024 Results Key Financial Results Revenue: US$11.2m (up by US$10.8m from... |
Delcath Systems Inc (DCTH) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...Delcath Systems Inc (DCTH) reports robust financial performance with significant milestones, despite anticipated seasonal challenges. |
Delcath Systems Reports Third Quarter 2024 Results and Business HighlightsQUEENSBURY, N.Y., November 08, 2024--Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the third quarter ended September 30, 2024. |
Delcath Systems to Participate in Upcoming Investor ConferencesQUEENSBURY, N.Y., November 01, 2024--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following upcoming investor conferences: |